FDA Clears Trial for ProNAi’s First Drug Candidate

ProNAi Therapeutics will begin Phase I trials with its first drug candidate, PNT2258, a potential treatment for several cancer types.

In preclinical research, PNT2258 has shown promising single-agent and combination-therapy efficacy as well as relevant drug-dose response in hematological and solid tumors, ProNAi said.

ProNAi also has partnered with Germany’s Novosom and Austria’s Polymun to develop liposome-based technologies to deliver its DNAi oligonucleotides.